GENTIBIO
LIVE

Serial Number

98478168

Owner

GentiBio, Inc.

Attorney

John V. Hobgood, Esquire

Filing Date

Apr 1, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GENTIBIO Trademark

Serial Number: 98478168

GENTIBIO is a trademark filed by GentiBio, Inc. on April 1, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

GentiBio, Inc.

150 CambridgePark Drive, 9th Floor
Cambridge, MA 02140

Entity Type: 03

Trademark Details

Filing Date

April 1, 2024

Registration Date

Not Registered

Published for Opposition

February 25, 2025

Goods & Services

Scientific research; Pharmaceutical and medical therapeutic research services; Medical research; Engineering of biological cells; Genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering

Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders, allergic diseases and disorders, autoimmune diseases and disorders, acute illness, diabetes, stroke, inflammation and inflammatory disease, respiratory and infectious diseases, acute respiratory distress illness, immunological disorders and metabolic diseases; Autologous therapies, namely, cells for medical purposes; Allogeneic therapies, namely, cells for medical purposes; Biological preparations for the treatment of cancer, namely, virotherapies; Human cells for medical purposes; Cells for medical therapy use; Cultured human cells for medical therapeutic use

Custom manufacture of pharmaceuticals and therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases, for others; Custom manufacturing of biological cells; Consultation in the field of custom manufacture of pharmaceuticals, therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases and biological cells

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 23, 2026 EXRA
SOU EXTENSION 2 GRANTED
Apr 22, 2026 EX2G
SOU EXTENSION 2 FILED
Apr 22, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 22, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 23, 2025 EXRA
SOU EXTENSION 1 GRANTED
Oct 22, 2025 EX1G
SOU EXTENSION 1 FILED
Oct 22, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 22, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 22, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 6, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 6, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 19, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 19, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 19, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 12, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 4, 2024 NWOS
NEW APPLICATION ENTERED
Apr 1, 2024 NWAP